Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Methods for treating infectious disease exacerbated asthma

An aggravating, infectious disease technology, applied in biochemical equipment and methods, antiviral agents, pharmaceutical formulations, etc., can solve problems such as weak activation ability

Inactive Publication Date: 2008-06-04
COLEY PHARM GRP INC +1
View PDF21 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

A class that effectively activates B cells but is relatively weak in inducing IFN-α and NK cell activation has been defined as class B

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Methods for treating infectious disease exacerbated asthma
  • Methods for treating infectious disease exacerbated asthma
  • Methods for treating infectious disease exacerbated asthma

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0203] 1. Induction of IFNα and IFN-related genes by CpG ODN (SEQ ID NO: 10)

[0204] method:

[0205] Mice (male BALB / c) received SEQ ID NO: 10 ( Figure 3a-3c The medium is 100μg / kg, Figure 3d-3f Medium is 10, 100 or 1000μg / kg) or saline. After 15 hours, analyze the secreted proteins (IFN α, IFN γ and IP10) in bronchial lavage fluid, or analyze the gene expression in lung tissue by real-time PCR after 30 hours.

[0206] result:

[0207] Class C CpG ODN induced the secretion of IFNα, IFNγ, and interferon-induced protein 10 (IP-10). The results are shown in Figure 3.

[0208] Because CpG ODN stimulated the secretion of IFNα in the airways of mice, we investigated whether the interferon-inducible indoleamine 2, 3 dioxygenase gene is expressed in the lungs. When CpG ODN was instilled into the airway, it did increase the expression of this immunomodulatory enzyme mRNA ( Figure 3f ). It also up-regulated Mx1 and indoleamine 2, 3 dioxygenase in the lungs of mice ( Figure 3d with 3e ). ...

Embodiment 2

[0226] We have shown that CpG oligodeoxynucleotides can inhibit mouse influenza virus load and virus-induced airway inflammation. In Example 2, we studied the protective effect of SEQ ID NO: 10 against the exacerbated airway inflammation induced by the combination of influenza virus infection and antigen stimulation.

[0227] method:

[0228] 1. Antigen and virus administration:

[0229] Mice (male BALB / c) were sensitized with antigen (cockroach, 10 μg, intraperitoneal) and aluminum hydroxide adjuvant (Pierce Alum) on day 0 and day 7 of the study.

[0230] The mice were subjected to antigen stimulation by contacting the intranasally administered antigen (10 μg, 40 μl saline solution) twice a week for three consecutive weeks. The first stimulation was performed on the 21st day of the study.

[0231] On the 34th day of the study (that is, before the last two antigen stimulations), the influenza virus (type A influenza, H1N1 subtype, mouse-adapted strain PR8, 200 EID) was injected i...

Embodiment 3

[0250] Induction of TLR9-related cytokines from mouse spleen cells in vitro and in vivo mouse lungs

[0251] The ability of SEQ ID NO: 10 to induce murine splenocytes to secrete TLR9-related cytokines in vitro was studied.

[0252] method

[0253] Stimulating cytokines from splenocytes in vitro

[0254] Spleen cells from 6 mice were pooled and incubated with ODN (0.1, 1, or 10 μg / ml) for 36 hours. The crushed mouse spleen was gently squeezed through a cell sieve (pore size 70 μm), and the cells were mechanically separated. Incubate in 1ml medium (RPMI 1640 containing 10% fetal bovine serum, all from Invitrogen, Carlsbad, CA, USA) (37°C, 5% CO 2 ) Cell (1×10 7 , Taken from 6 mice). Add SEQ ID NO: 10 or control ODN (with reverse CpG motif) or any one of the two domains of SEQ ID NO: 10 (5' terminal stimulation sequence and palindrome), the given concentration is 0.1, 1 or 10μg / ml. After 24 hours of incubation, the secreted cytokines (IFNα, IFNγ, interferon-inducing protein [IP]-10...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present invention provides a method for treating infectious disease exacerbated asthma, comprising administering an effective amount of a CpG oligonucleotide to an asthmatic individual, particularly the infectious disease exacerbated asthma may be virus exacerbated asthma.

Description

Invention field [0001] The present invention generally relates to methods of using immunostimulatory oligonucleotides and their compositions to treat asthma exacerbated by infectious diseases. technical background [0002] Bacterial DNA has the immunostimulatory effect of activating B cells and natural killer cells, but vertebrate DNA does not (Tokunaga, T. et al., 1988. Jpn. J. Cancer Res. 79: 682-686; Tokunaga, T. et al., 1984 , JNCI 72: 955-962; Messina, JP et al., 1991, J. Immunol. 147: 1759-1764; and Krieg, 1998 in the "Applied Oligonucleotide Technology" review; CA.Stein and AMKrieg eds, John Wiley and Sons, Inc., New York, NY, pages 431-448). It is now clear that these immunostimulatory effects of bacterial DNA are the result of the presence of unmethylated CpG dinucleotides in a special base environment (CpG motif). CpG motifs are ubiquitous in bacterial DNA, but in It is methylated in vertebrate DNA and is not representative (Krieg et al., 1995 Nature 374:546-549; Krieg,...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): A61K31/7088C12N15/117
CPCC12N15/117A61K31/7088A61K2039/55561C12N2310/17A61K31/713A61K39/39A61P11/06A61P31/16A61P37/04
Inventor A·M·克里格G·T·德桑克提斯S·L·安德伍德R·A·贾普J·A·小施密特
Owner COLEY PHARM GRP INC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com